Patients with atopic dermatitis maintain improvements for up to 2 years with lebrikizumab

WASHINGTON — Patients with moderate to severe atopic dermatitis treated with lebrikizumab maintained improvements in patient-reported outcomes, according to a poster presented here.
In the study, findings of which were presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting, David Rosmarin, MD, of Indiana University School of Medicine, and colleagues evaluated the impact of lebrikizumab on AD signs and symptoms.
Patients from ADjoin, the long-term extension of the ADvocate 1, ADvocate 2 and ADhere trials, were instructed to complete the Patient Oriented Eczema

WASHINGTON — Patients with moderate to severe atopic dermatitis treated with lebrikizumab maintained improvements in patient-reported outcomes, according to a poster presented here.
In the study, findings of which were presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting, David Rosmarin, MD, of Indiana University School of Medicine, and colleagues evaluated the impact of lebrikizumab on AD signs and symptoms.
Patients from ADjoin, the long-term extension of the ADvocate 1, ADvocate 2 and ADhere trials, were instructed to complete the Patient Oriented Eczema